

VICURON PHARMACEUTICALS INC

Form 8-K

May 06, 2004

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**  
**SECURITIES EXCHANGE ACT OF 1934**

**Date of report (Date of earliest event reported):**

**March 31, 2004**

---

**Vicuron Pharmaceuticals Inc.**

(Exact Name of Registrant As Specified in its Charter)

---

**Delaware**  
(State or Other Jurisdiction

of Incorporation)

**000-31145**  
(Commission File Number)

**04-3278032**  
(I.R.S. Employer  
Identification Number)

Edgar Filing: VICURON PHARMACEUTICALS INC - Form 8-K

**455 South Gulph Road, Suite 305, King of Prussia, PA 19406**

**(Address of Principal Executive Offices) (Zip Code)**

**(610) 205-2300**

**(Registrant's telephone number, including area code)**

**not applicable**

**(Former Name or Former Address, if Changed Since Last Report.)**

---

**Item 7. Exhibits.**

The exhibit listed on the Exhibit Index (following this Report's signature page) is furnished with this Report.

**Item 12. Results of Operations and Financial Condition.**

On May 6, 2004, Vicuron Pharmaceuticals Inc. issued a press release regarding its financial results for the three months ended March 31, 2004. A copy of the press release announcing these financial results is attached as Exhibit 99.1.

The information (including the exhibit incorporated into this Item 12 by reference) shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in such a filing.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

VICURON PHARMACEUTICALS INC.  
(Registrant)

Date: May 6, 2004

By: /s/ GEORGE F. HORNER III

---

George F. Horner III  
President and Chief Executive Officer

**EXHIBIT INDEX**

Pursuant to Item 601(a)(2) of Regulation S-K, this exhibit index immediately precedes the exhibit.

<b><u>Exhibit No.</u></b>	<b><u>Description</u></b>
99.1	Press release of Vicuron Pharmaceuticals Inc. dated May 6, 2004, reporting its financial results for the three months ended March 31, 2004.